Discontinuation of PTH therapy amplifies bone loss by increasing oxidative stress: An event ameliorated by sequential IL-17 neutralizing antibody therapy
Osteoporosis leads to excessive bone resorption which is not accompanied by equal amount of bone formation. PTH (1−34) forms the mainstay of bone anabolic therapy. Intermittent PTH (iPTH) has the ability to reconstruct skeleton, a property not shared by other anti-resorptives. In initial phases of P...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Elsevier
2022
|
| Subjects: | |
| Online Access: | https://doaj.org/article/4fd26d8fb43d4d9ab0581fffa0b40601 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|